William Edwards
Rheumatology · Summerville, SCNPI 1952409997
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), ownership interests and royalties or licence payments — rather than concentrated in one kind of arrangement. American Rheumatology Network, LLC accounts for 99.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $450,000, more than ten times the $749 reported in 2019. Among rheumatology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $24,340 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- American Rheumatology Network, LLC$1.3M
- Novartis$127
- UCB, Inc.$118
- AbbVie$83
- Merck$77
- Gilead$67
- plus $277 from 9 others
Across 82 payments — averaging $6992.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$234K
- GSK$156K
- Pfizer$83K
- Gilead$82K
- Regeneron$17K
- Amgen$1K
Across 6 payments — averaging $676,552 each. An ownership or investment interest held by the physician or an immediate family member.
- American Rheumatology Network, LLC$4.1M
What the payments were for
- Royalty or licence$310,71224%
- Consulting fees$654,12151%
- Food & beverage$7490%
- Ownership interest$324,43225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| American Rheumatology Network, LLC | 5 | $1,289,264 |
| Novartis | 9 | $127 |
| UCB, Inc. | 8 | $118 |
| AbbVie | 5 | $83 |
| Merck | 6 | $77 |
| Gilead | 1 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $56 |
| Lilly USA, LLC | 3 | $42 |
| Genentech USA, Inc. | 2 | $37 |
| Pfizer | 3 | $37 |
| AstraZeneca | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| GSK | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $12 |
| Amgen | 1 | $11 |
How this compares
$1,290,013 in reported general payments places this provider in the 95th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Summerville
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- Nicholas HoldgateSummerville$23K
- Bradley CollinsSummerville$6K
- Durga AdhikariSummerville$5K
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.